VisualAbstract: Combined cagrilintide and semaglutide for weight management well tolerated in early clinical trials 2 Minute Medicine CagriSema Weight Loss Injection Results Safety UK Update In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide + Semaglutide Weight Loss Peptides FactorPeptides In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot